3545 results about "Oxygen atom" patented technology

An organic EL element includes an organometallic complex including a rhenium atom; one ligand which has a coordinated nitrogen atom and a coordinated oxygen atom, each coordinated with the rhenium atom, and has at least one π conjugation part; and the other ligand coordinated with the rhenium atom in such a way that the ligand saturates the coordination number of the rhenium atom and the charge of the whole organometallic complex is neutral.

The triazinewherein Ar1, Ar2, Ar3, and Ar4 are each independently an aryl; R1 and R2 are substituents selected from the group consisting of hydrogen, an alkyl, an aryl, an alkoxy, a halogen atom, and a cyano; R3 and R4 are each a divalent group L selected from the group consisting of -C(R'R'')-, alkylene, an oxygen atom, a sulfur atom, and -Si(R'R'')-, wherein R' and R'' are selected from the group consisting of hydrogen, alkyl, alkoxy, and aryl.

Provision of a novel platinum complex which is useful as a material for a light-emitting device of good light emission characteristic and light emission efficiency, and a novel light-emitting material that may be utilized in various fields.

A platinum complex represented by the following general formula (1):

(in which two rings of ring A, ring B, ring C, and ring D represent nitrogen-containing heterocyclic rings which may have a substituent and the remaining two rings of them represent aryl rings or hetero aryl rings which may have a substituent, the ring A and the ring B, the ring A and the ring C or/and the ring B and the rind D may form condensed rings. Two of X¹, X², X³, and X⁴ represent nitrogen atoms coordination bonded to a platinum atom and the remaining two of them represent carbon atoms or nitrogen atoms. Q¹, Q², and Q³ each represents a bond, oxygen atom, sulfur atom or bivalent group, two of Z¹, Z², Z³, and Z⁴ represent coordination bonds, and the remaining two of them represent covalent bonds, oxygen atoms or sulfur atoms), and a light-emitting device containing the platinum complex.

A multilayered material is provided which includes a substrate and a silicon-containing film formed on the substrate, wherein the silicon-containing film has a nitrogen-rich area including silicon atoms and nitrogen atoms, or silicon atoms, nitrogen atoms, and an oxygen atoms and the nitrogen-rich area is formed by irradiating a polysilazane film formed on the substrate with an energy beam in an atmosphere not substantially including oxygen or water vapor and denaturing at least a part of the polysilazane film. A method of producing the multilayered material is also provided.

The present invention relates to a heterocyclic compound of the following general formula (I):wherein X is sulfur atom, oxygen atom or -NR3- (R3 may form a heterocyclic ring or a substituted heterocyclic ring with R1 via the nitrogen atom),R1 is alkyl group, substituted alkyl group, aryl group, substituted aryl group, heterocyclic group or substituted heterocyclic group, andR2 is hydrogen atom, halogen atom etc.;or its pharmaceutically acceptable salt and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases comprising the compound (I) or its pharmaceutically acceptable salt as active ingredients.

The present invention provides a method and apparatus for forming an insulating film having good reliability, in accordance with a process without high-temperature heating. In accordance with the present invention, in a process for forming an insulating film for a semiconductor device by oxidizing a material to be processed, exposed at the surface of a substrate to be processed, in accordance with plasma oxidation method, the plasma processing is carried out by use of at least a gas that contains hydrogen atoms other than H₂ and H₂O and a gas that contains oxygen atoms other than H₂O.

Disclosed is a producing method of a semiconductor device including: loading at least one substrate into a processing chamber; forming a metal oxide film or a silicon oxide film on a surface of the substrate by repeatedly supplying a metal compound or a silicon compound, each of which is a first material, an oxide material which is a second material including an oxygen atom, and a hydride material which is a third material, into the processing chamber predetermined times; and unloading the substrate from the processing chamber.

A photochemical sensing system enables the measurement of nitrogen oxides (nitrogen dioxide and nitric oxide) by photolyzing nitrogen dioxide to form oxygen atoms which combine with oxygen molecules to form ozone. Ozone reacts with nitric oxide to for nitrogen dioxide-decreasing ozone. Changes in ozone concentration are measured as a surrogate for the nitrogen dioxide and nitric oxide. Any species which photolyzes to yield oxygen atoms may be measured by this technique. Additional specificity for nitrogen oxides is conferred by allowing the nitric oxide to react with the ozone to recreate the nitrogen dioxide. By periodically photolyzing the nitrogen dioxide (to form ozone), and then allowing the resulting nitric oxide to react with the ozone (thereby reducing ozone), a pulsed signal is obtained whose amplitude is proportional to the total amount of nitrogen dioxide and nitric oxide present. Medical applications include measuring nitric oxide concentrations in expired air samples.

The present invention provides a fluorinated surfactant having the general formula:

[R_f—(O)_t—CQH—CF₂—O]_n—R-G  (I)

wherein R_f represents a partially or fully fluorinated aliphatic group optionally interrupted with one or more oxygen atoms, Q is CF₃ or F, R is an aliphatic or aromatic hydrocarbon group, G represents a carboxylic or sulphonic acid or salt thereof, t is 0 or 1 and n is 1, 2 or 3. The surfactant is particularly useful in polymerizing fluorinated monomers in an aqueous emulsion polymerization.

An 8-oxoadenine compound useful as an immuno-modulator having specific activity against Th1/Th2, specifically a prophylactic and therapeutic agent for a topical application for allergic diseases, viral diseases and cancers, which is represented by the following formula (1):

wherein A is a group of a formula represented by the formula (2):

• • wherein R² is a substituted or unsubstituted alkyl group and so on, R³ is hydrogen atom or an alkyl group, R is a halogen atom and so on, n is 0˜2,
• X¹ is oxygen atom, Z is straight or branched chain alkylene, and R¹ is an alkyl group which is optionally substituted by hydroxy group, an alkoxy group, alkoxycarbonyl group and so on, or its pharmaceutically acceptable salt.

A 4-membered compound is represented by the following formula (I) is disclosed (in the formula, X1 and X2 each independently represent an oxygen atom, a sulfur atom or a substituted or unsubstituted imino group, Y1 and Y2 each independently represent a single bond, an oxygen atom or a substituted or unsubstituted imino group, B1 and B2 each independently represent an optionally substituted aliphatic, aliphatic carbonyl, aromatic or aromatic carbonyl group having 1-20 carbon atoms, and A1 and A2 each independently represent a group represented by the following formula (II) (Ar1, Ar2 and Ar3 each independently represent a cyclic group having 5-14 carbon atoms, L1 and L2 each independently represent a single bond or a divalent linking group, and p represents an integer of 0-2)). There is also disclosed a birefringence medium containing a 4-membered compound represented by the formula (I) and an optical element comprising the birefringence medium.

The coverage characteristics or loading effect of an oxide film can be improved without having to increase the supply amount or time of an oxidant. There is provided method of manufacturing a semiconductor device. The method comprises loading at least one substrate to a processing chamber; forming an oxide film on the substrate by alternately supplying a first reaction material and a second reaction material containing oxygen atoms to the processing chamber while heating the substrate; and unloading the substrate from the processing chamber, wherein the forming of the oxide film is performed by keeping the substrate at a temperature equal to or lower than a self-decomposition temperature of the first reaction material and irradiating ultraviolet light to the second reaction material.

A method for producing a photoelectric conversion device comprising a conductive support and a photosensitive layer containing a semiconductor fine particle on which a dye is adsorbed, wherein the semiconductor fine particle is treated with a compound represented by the following general formula (I): wherein X represents an oxygen atom, a sulfur atom, a selenium atom or NY, in which Y represents a hydrogen atom, an aliphatic hydrocarbon group, a hydroxyl group or an alkoxy group; R1, R2, R3 and R4 independently represent a hydrogen atom, an aliphatic hydrocarbon group, an aryl group, a heterocyclic group, -N(R5)(R6), -C(=O)R7, -C(=S)R8, -SO2R9 or -OR10; R5 and R6 few independently have the same meaning as the R1, R2, R3 and R4; R7, R8 and R9 independently represent a hydrogen atom, an aliphatic hydrocarbon group, an aryl group, a heterocyclic group, -N(R5)(R6), -OR10 or -SR11; and R10 and R11 independently represent a hydrogen atom or an aliphatic hydrocarbon group.

A main chain-type or side chain-type polymeric compound having a structure wherein at least one metal complex segment having a plurality ligands is introduced into a main chain or a side chain is provided. In the case where the polymeric compound is the main chain-type polymeric compound, the metal complex segment has at least one ligand constituting a polymer main chain of the polymeric compound and having a carbon atom and oxygen atom bonded to a metal atom. On the other hand, in the case where the polymeric compound is the side chain-type polymeric compound, a polymer main chain thereof has a conjugated structure, preferably a conjugated double bond. A ligand for the polymeric compound includes a chain or cyclic ligand, of which a bidentate ligand having an organic cyclic structure is preferred, and the ligand has at least one carbon atom or oxygen atom and is bonded to a center metal atom, preferably iridium, via the carbon atom or oxygen atom. In a case of forming a luminescence layer by using the polymeric compound as a luminescent material, a resultant organic luminescence device is less liable to cause a concentration extinction and is a high-luminescence efficiency device excellent in stability.

A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1):

[wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X¹ represents oxygen, sulfur, NR¹ (R¹ represents hydrogen or alkyl), or a single bond; Y¹ represents a single bond, alkylene, etc.; Y² represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q¹ and Q² represents —COOR¹⁰ (wherein R¹⁰ represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

The present invention is a light emitting device material characterized by containing an anthracene compound represented by the following general formula (1) or general formula (3), and the present invention allows a light emitting device having high luminous efficiency and excellent durability.

(R¹ to R¹⁰ are a hydrogen atom, alkyl group, cycloalkyl group, heterocyclic group or the like. At least one of the R¹ to R¹⁰ is a substituent represented by the following general formula (2).)

(R¹¹ to R¹⁸ are a hydrogen atom, alkyl group and cycloalkyl group. X is an oxygen atom or sulfur atom, and Y is a single bond; arylene group or heteroarylene group. Any one of the R¹¹ to R¹⁸ is used for linking with Y, and α is used for linking with the anthracene skeleton.)

(R¹⁹ to R³⁷ are a hydrogen atom, alkyl group, cycloalkyl group, heterocyclic group or the like. n is 1 or 2. A is a heteroarylene group or arylene group. Any one of the R¹⁹ to R²⁷ and any one of the R²⁸ to R³⁷ are used for linking with A.)

A method of fabricating a silicon-on-insulator structure having a silicon surface layer in a semiconductor workpiece, is carried out by maintaining the workpiece at an elevated temperature and producing an oxygen-containing plasma in the chamber while applying a bias to the workpiece and setting the bias to a level corresponding to an implant depth in the workpiece below the silicon surface layer to which oxygen atoms are to be implanted, whereby to form an oxygen-implanted layer in the workpiece having an oxygen concentration distribution generally centered at the implant depth and having a finite oxygen concentration in the silicon surface layer. The oxygen concentration in the silicon surface layer is then reduced to permit epitaxial silicon deposition.

The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I):

wherein represents a single bond or a double bond; Ar₁ represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R¹ and R² each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z₁ represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.

PCT No. PCT/US97/22760 Sec. 371 Date Jun. 10, 1999 Sec. 102(e) Date Jun. 10, 1999 PCT Filed Dec. 12, 1997 PCT Pub. No. WO98/26315 PCT Pub. Date Jun. 18, 1999A planar optical device is formed on a substrate (12) and comprising an array of waveguide cores (14) and a cladding layer (16) formed contiguously with the cores. At least one of the array of waveguide cores (14) and the cladding layer (16) is an inorganic-organic hybrid material that comprises an extended matrix containing silicon and oxygen atoms with at least a fraction of the silicon being directly bonded to substituted or unsubstituted hydrocarbon atoms. In accordance with other embodiments of the invention, a method of forming an array of cores comprises the steps of preparing a core composition precursor material; partially hydrolyzing and polymerizing the material; forming an array of waveguide cores under conditions effective to form an inorganic-organic hybrid material that comprises an extended matrix containing silicon and oxygen atoms with at least a fraction of the silicon being directly bonded to substituted or unsubstituted hydrocarbon atoms.

An organic electroluminescent device having a pair of electrodes and at least one organic layer including a light-emitting layer interposed between the pair of electrodes, in which the organic layer contains at least one compound represented by formula (I):

wherein Z¹ and Z² each independently represent a nitrogen-containing heterocycle coordinated with the platinum through a nitrogen atom; Q¹ and Q² each independently represent a group bonded with the platinum through a carbon atom, an oxygen atom, a sulfur atom, a nitrogen atom or a phosphorous atom; Q¹ and Q² each represent a structure different from each other; L¹ and L² each independently represent a single bond or a linking group; and n represents 0 or 1.

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I:

and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A¹ is N or CR¹; A³ is N or CR³; A⁵ is N or CR⁵; R¹, R³-R⁶ and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

The present invention provides a novel pyrimidine compound having an excellent adenosine receptor (A₁, A_2A, A_2B receptor) antagonistic action. More specifically, it provides a compound represented by the following formula, a salt thereof or a solvate of them.

In the formula, R¹ and R² are the same as or different from each other and each represents a hydrogen atom, an alkyl group having one to six carbon atoms which may be substituted, an alkenyl group having two to six carbon atoms which may be substituted, an alkynyl group having two to six carbon atoms which may be substituted, a cycloalkyl group having three to eight carbon atoms which may be substituted, a cycloalkenyl group having three to eight carbon atoms which may be substituted, a 5 to 14-membered non-aromatic heterocyclic group which may be substituted, an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted, an acyl group having one to six carbon atoms which may be substituted or an alkylsulfonyl group having one to six carbon atoms which may be substituted; R³ represents a hydrogen atom, a halogen atom, a cyano group, an alkyl group having one to six carbon atoms which may be substituted, an alkenyl group having two to six carbon atoms which may be substituted, an alkynyl group having two to six carbon atoms which may be substituted, an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted, a nitrogen atom which may be substituted, an oxygen atom which may be substituted or a sulfur atom which may be substituted; R⁴ represents an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted or a 5 to 14-membered non-aromatic heterocyclic group having at least one or more unsaturated bonds which may be substituted; and R⁵ represents an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted or a 5 to 14-membered aromatic heterocyclic group which may be substituted.

The present invention provides a high-capacity and low-cost non-aqueous electrolyte secondary battery, comprising: a negative electrode containing, as a negative electrode active material, a ssubstance capable of absorbing/desorbing lithium ions and/or metal lithium; a separator; a positive electrode; and an electrolyte, wherein the positive electrode active material contained in the positive electrode is composed of crystalline particles of an oxide containing two kinds of transition metal elements, the crystalline particles having a layered crystal structure, and oxygen atoms constituting the oxide forming a cubic closest packing structure.